Induced Infringement

Automatically clustered newsroom coverage around one of the most active themes in the intellectual property ecosystem.

PatentsUSA

Supreme Court Unanimously Rules Against Induced Infringement Claim in Hikma v. Amarin, Clarifying Standards for Generic Drug Labeling

In a unanimous decision, the U.S. Supreme Court ruled that Amarin Pharma failed to state a claim for active inducement of patent infringement against Hikma Pharmaceuticals. The Court clarified that generic drugmakers using "skinny labels" compliant with FDA regulations and industry practice do not induce infringement…

Friday, June 5, 2026

PatentsUSA

Supreme Court to Address Induced Infringement Claims in Generic ‘Skinny Label’ Drug Marketing Dispute

The U.S. Supreme Court has granted certiorari in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. to resolve whether generic drug makers’ marketing statements can support inducement claims of patent infringement when using skinny labels that omit patented uses. The case tests the boundaries of Hatch-Waxman’s Sect…

Wednesday, January 28, 2026

Newsletters & Digests

Follow Induced Infringement

Subscribe to receive daily and weekly newsroom coverage aligned to this trend cluster and adjacent IP developments.

Explore

All newsroom coverage Filtered archive